STOK
Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.81
−0.60%Margins
Gross margin
84.7%
EBITDA margin
-744.4%
EBIT margin
-809.7%
Net margin
-753.6%
FCF margin
-654.9%
-60.2%
Return on equity
-52.8%
Return on assets
-64.1%
Return on invested capital
0.07x
Asset turnover
-$178.0M
Cash from operations
$4.54
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026